Literature DB >> 27429517

Is JAK2V617F Mutation the Only Factor for Thrombosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms?

Mehmet Sevki Uyanik1, Mehmet Baysal2, Gulsum Emel Pamuk3, Muhammet Maden1, Mustafa Akker2, Elif Gulsum Umit1, Muzaffer Demir1, Erkan Aydogdu2.   

Abstract

The most common genetic disorder in Philadelphia negative chronic myeloproliferative neoplasms is the JAK2-V617F mutation. In the present study, we aimed to determine risk factors for thrombosis in patients with essential thrombocytosis and polycythemia vera. We screened the medical records of 101 patients. Risk factors which may predict thrombosis were recorded. Venous thrombosis (VT) before diagnosis was significantly higher in JAK2 positive patients. VT after diagnosis was similar in JAK2 positive and negative groups, and was significantly higher in elderly patients. Treatment places importance on the JAK2 mutation under unmodifiable cardiovascular risk factors such as advanced age after diagnosis.

Entities:  

Keywords:  Allele burden; Chronic myeloproliferative neoplasms; JAK2 mutation; Thrombosis

Year:  2015        PMID： 27429517      PMCID： PMC4930758          DOI： 10.1007/s12288-015-0578-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


  26 in total

1.  The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.

Authors:  Betty Cheung; Deepti Radia; Panagiotis Pantelidis; Ghasem Yadegarfar; Claire Harrison
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

2.  Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.

Authors:  Issa J Dahabreh; Katerina Zoi; Stavroula Giannouli; Christine Zoi; Dimitrios Loukopoulos; Michael Voulgarelis
Journal:  Leuk Res       Date:  2008-07-15       Impact factor: 3.156

3.  The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.

Authors:  Ayalew Tefferi; Terra L Lasho; Susan M Schwager; Jacob S Strand; Michelle Elliott; Ruben Mesa; Chin-Yang Li; Martha Wadleigh; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

Review 4.  Thrombotic disease in the myeloproliferative neoplasms.

Authors:  Anna Falanga; Marina Marchetti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

Review 5.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

6.  JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

Authors:  Giovanni Barosi; Gaetano Bergamaschi; Monia Marchetti; Alessandro M Vannucchi; Paola Guglielmelli; Elisabetta Antonioli; Margherita Massa; Vittorio Rosti; Rita Campanelli; Laura Villani; Gianluca Viarengo; Elisabetta Gattoni; Giancarla Gerli; Giorgina Specchia; Carmine Tinelli; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2007-08-21       Impact factor: 22.113

7.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  S Cortelazzo; G Finazzi; M Ruggeri; O Vestri; M Galli; F Rodeghiero; T Barbui
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

8.  Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders.

Authors:  Christine Bellanné-Chantelot; Isabelle Chaumarel; Myriam Labopin; Florence Bellanger; Véronique Barbu; Claudia De Toma; François Delhommeau; Nicole Casadevall; William Vainchenker; Gilles Thomas; Albert Najman
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

9.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

10.  JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.

Authors:  Alessandra Carobbio; Guido Finazzi; Elisabetta Antonioli; Paola Guglielmelli; Alessandro M Vannucchi; Chiara M Dellacasa; Silvia Salmoiraghi; Federica Delaini; Alessandro Rambaldi; Tiziano Barbui
Journal:  Exp Hematol       Date:  2009-06-24       Impact factor: 3.084
View more
  2 in total

1.  Myeloproliferative Neoplasms, an Acquired Thrombophilic State: JAK2 and Beyond.

Authors:  Hara Prasad Pati; Prashant Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-17       Impact factor: 0.900

2.  Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.

Authors:  Maroua Abdelghani; Haifa Hammami; Wiem Zidi; Hassiba Amouri; Hind Ben Hadj Othmen; Ahlem Farrah; Samia Menif
Journal:  J Clin Lab Anal       Date:  2022-06-26       Impact factor: 3.124
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.